Potential therapeutic agents against COVID-19: What we know so far

153Citations
Citations of this article
595Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavirin, tocilizumab, and sarilumab. More clinical trials are being conducted for further confirmation of the efficacy and safety of these agents in treating COVID-19.

Cite

CITATION STYLE

APA

Lu, C. C., Chen, M. Y., Lee, W. S., & Chang, Y. L. (2020). Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association, 83(6), 534–536. https://doi.org/10.1097/JCMA.0000000000000318

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free